Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination.

Proceedings of the National Academy of Sciences of the United States of America
Viggo Van TendelooZwi Nisan Berneman

Abstract

Active immunization using tumor antigen-loaded dendritic cells holds promise for the adjuvant treatment of cancer to eradicate or control residual disease, but so far, most dendritic cell trials have been performed in end-stage cancer patients with high tumor loads. Here, in a phase I/II trial, we investigated the effect of autologous dendritic cell vaccination in 10 patients with acute myeloid leukemia (AML). The Wilms' tumor 1 protein (WT1), a nearly universal tumor antigen, was chosen as an immunotherapeutic target because of its established role in leukemogenesis and superior immunogenic characteristics. Two patients in partial remission after chemotherapy were brought into complete remission after intradermal administration of full-length WT1 mRNA-electroporated dendritic cells. In these two patients and three other patients who were in complete remission, the AML-associated tumor marker returned to normal after dendritic cell vaccination, compatible with the induction of molecular remission. Clinical responses were correlated with vaccine-associated increases in WT1-specific CD8+ T cell frequencies, as detected by peptide/HLA-A*0201 tetramer staining, and elevated levels of activated natural killer cells postvaccination. ...Continue Reading

References

Jan 26, 1995·The New England Journal of Medicine·B Löwenberg
Sep 30, 1999·The New England Journal of Medicine·B LöwenbergA Burnett
Mar 14, 2003·Current Opinion in Immunology·Pierre G Coulie, Pierre van der Bruggen
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
May 22, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Aude BonehillKris Thielemans
Sep 2, 2004·Nature Medicine·Steven A RosenbergNicholas P Restifo
Sep 15, 2004·Proceedings of the National Academy of Sciences of the United States of America·Yoshihiro OkaHaruo Sugiyama
Aug 27, 2005·Leukemia·A Van DriesscheV F I Van Tendeloo
Nov 8, 2005·Cancer Immunology, Immunotherapy : CII·Takuya OsadaMichael A Morse
Dec 20, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Katayoun RezvaniA John Barrett
Feb 3, 2006·Expert Review of Vaccines·Christopher Y WooTakuya Osada
Apr 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hélène LapillonneJudith Landman-Parker
Jul 28, 2006·Current Opinion in Immunology·Sylvie Rusakiewicz, Jeffrey J Molldrem
Sep 2, 2006·Cancer Immunology, Immunotherapy : CII·Jon Amund KyteGustav Gaudernack
Nov 28, 2006·Lancet·Elihu Estey, Hartmut Döhner
Mar 16, 2007·Leukemia·L YangM D Minden
Jul 20, 2007·Leukemia·D Ribatti
Sep 6, 2007·Cancer·Farhad RavandiHagop M Kantarjian
May 27, 2008·Current Opinion in Immunology·Yoshihiro OkaHaruo Sugiyama
Jul 12, 2008·Cancer Immunology, Immunotherapy : CII·E H J G AarntzenI J M de Vries
Sep 19, 2008·Immunity·Cornelis J M Melief
Nov 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jochen GreinerMichael Schmitt
Feb 18, 2009·Cancer Immunology, Immunotherapy : CII·Jon Amund KyteGustav Gaudernack
Apr 23, 2009·International Journal of Cancer. Journal International Du Cancer·Yusuke OjiHaruo Sugiyama
Aug 7, 2009·Human Gene Therapy·Evelien L J M SmitsViggo F I Van Tendeloo
Aug 25, 2009·Nature Reviews. Cancer·Maurizio Bendandi

❮ Previous
Next ❯

Citations

Aug 26, 2011·Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society·Kimberly Noonan, Ivan Borrello
Nov 9, 2010·Asian Journal of Andrology·Derek Hart
Feb 4, 2012·Gene Therapy·B R AndersonD Weissman
Feb 9, 2011·Immunology and Cell Biology·Marie Bleakley, Stanley R Riddell
Jan 29, 2011·Leukemia·S AnguilleE L J M Smits
Apr 7, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·Jeanette E BoudreauYonghong Wan
Mar 1, 2012·Molecular Therapy : the Journal of the American Society of Gene Therapy·An M T Van NuffelAude Bonehill
May 8, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·M Sarah S BovenbergBakhos A Tannous
Jan 15, 2013·Human Gene Therapy·Bala Sai SundarasettyRenata Stripecke
Jan 10, 2012·Current Opinion in Hematology·Yishai Ofran, Jacob M Rowe
Feb 9, 2012·Current Opinion in Hematology·Courtney D DiNardo, Selina M Luger
Sep 29, 2011·The Cancer Journal·Christopher S Hourigan, Hyam I Levitsky
Sep 29, 2011·The Cancer Journal·Gerold Schuler
Oct 27, 2011·Clinical & Developmental Immunology·Norimitsu Kadowaki, Toshio Kitawaki
Jul 11, 2012·Clinical & Developmental Immunology·R CornelissenJ P J J Hegmans
Jun 8, 2011·The Journal of Clinical Investigation·Norman WollerFlorian Kühnel
Jan 14, 2011·Journal of Immune Based Therapies and Vaccines·Sandra Tuyaerts
Jul 12, 2011·Journal of Translational Medicine·Cornelis J M MeliefDavid F Stroncek
Aug 22, 2012·The Oncologist·Eva LionViggo F I Van Tendeloo
Apr 26, 2012·Biologics : Targets & Therapy·Inge LangersNathalie Jacobs
Sep 10, 2011·Drugs·Katayoun Rezvani, Hugues de Lavallade
Oct 15, 2011·Immunotherapy·Nathalie CoolsLuigi Buonaguro
Jan 1, 2014·International Journal of Hematology·Toshio Kitawaki
Dec 18, 2013·Immunotherapy·Mario Arpinati, Antonio Curti
Dec 22, 2012·Immunotherapy·Felix S LichteneggerMarion Subklewe
Nov 8, 2012·Future Oncology·Jessica A CintoloBrian J Czerniecki
Jul 23, 2013·Blood Reviews·Anna MartnerKristoffer Hellstrand
Jul 9, 2014·Nature Reviews. Clinical Oncology·Ignacio MeleroHåkan Mellstedt
Aug 21, 2013·Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine·Masahiro Ogasawara
Sep 5, 2014·Cancer Immunology, Immunotherapy : CII·Marion SubkleweIris Bigalke
Sep 3, 2014·Journal of the National Cancer Institute·Antonino BrunoDouglas M Noonan
Jan 5, 2014·Cancer Immunology, Immunotherapy : CII·Jurjen M RubenArjan A van de Loosdrecht
Oct 22, 2010·Cancer Immunology, Immunotherapy : CII·Jürgen KuballMatthias Theobald
Apr 27, 2011·Cancer Immunology, Immunotherapy : CII·Evelien L J SmitsBarbara-Ann Guinn
Sep 23, 2014·Nature Reviews. Drug Discovery·Ugur SahinÖzlem Türeci

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.